Pharma Journalist -

SMi Reports: Jessica Shull from Digital Therapeutics Alliance to present at Disruptive Technologies in Pharma conference in London on the 20th and 21st January The highly anticipated…
Read More...

Pfenex Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the new drug application for PF708 submitted under the 505(b)(2) regulatory pathway, with Forteo…
Read More...

Akcea Therapeutics, and Pfizer announced that the companies have entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being…
Read More...

SMi Group Reports: CSO of Optceutics Ltd to present at SMi’s Ophthalmic Drugs conference commencing on 18th- 20th November 2019, in London The Ophthalmic Drugs conference will take…
Read More...

SMi Reports: Four interactive sessions will take place at the inaugural Respiratory Drug Delivery conference to be held on the 6th December in London. SMi is pleased to provide…
Read More...

SMi Reports: RNA Therapeutics conference and focus day to return on February 2020, in London SMi Group is proud to announce the return of RNA Therapeutics conference for its 11th…
Read More...

AstraZeneca announced that the US Food and Drug Administration (FDA) has approved the self-administration of Fasenra (benralizumab) in a pre-filled, single-use auto-injector (the…
Read More...

Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, announced it entered…
Read More...

Prometheus Biosciences, Inc., a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and…
Read More...

Merck, known as MSD outside the United States and Canada, announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has been approved by the National Medical Products Administration (NMPA) in…
Read More...